Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).
Inclusion Criteria:
Exclusion Criteria:
Genova, 16132, Italy
Kita-adachi-gun, Saitama 3620806, Japan
Sunto-gun, Shizuoka 4118777, Japan
Chuo-ku, Tokyo 1040045, Japan
Koto-ku, Tokyo 1358550, Japan
Shinjuku-ku, Tokyo 1608582, Japan
Surrey, SM2 5PT, United Kingdom